Free tool
FAERS Monitor: Reglan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017862 or its brand name (Reglan, Metoclopramide Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
26,247
Serious
21,440
82% of reports
Hospitalization
9,138
Death reported
2,766
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- tardive dyskinesia6,603
- extrapyramidal disorder3,954
- dystonia2,529
- nausea2,484
- vomiting1,729
- diarrhoea1,368
- pain1,327
- fatigue1,283
- incorrect drug administration duration1,264
- dyspnoea1,208
- asthenia1,039
- headache1,023
- off label use1,011
- abdominal pain917
- anxiety912
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 525 |
| 2005 | 571 |
| 2006 | 566 |
| 2007 | 563 |
| 2008 | 594 |
| 2009 | 832 |
| 2010 | 1,178 |
| 2011 | 4,035 |
| 2012 | 3,769 |
| 2013 | 1,211 |
| 2014 | 934 |
| 2015 | 843 |
| 2016 | 980 |
| 2017 | 1,062 |
| 2018 | 916 |
| 2019 | 1,028 |
| 2020 | 966 |
| 2021 | 925 |
| 2022 | 1,156 |
| 2023 | 1,049 |
| 2024 | 976 |
| 2025 | 912 |
| 2026 | 649 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,027,912 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| tardive dyskinesiaSignal | 6,603 | 244.5 | 238.5 | 1,228,263 |
| extrapyramidal disorderSignal | 3,954 | 151.5 | 146.8 | 497,709 |
| dystoniaSignal | 2,529 | 120.0 | 115.3 | 259,678 |
| incorrect drug administration durationSignal | 1,264 | 37.7 | 35.6 | 43,101 |
| abdominal painSignal | 917 | 3.2 | 3.0 | 1,368 |
| vomitingSignal | 1,729 | 3.0 | 2.8 | 2,276 |
| anxietySignal | 912 | 2.6 | 2.4 | 885 |
| nauseaSignal | 2,484 | 2.5 | 2.4 | 2,357 |
| astheniaSignal | 1,039 | 2.2 | 2.1 | 704 |
| pain | 1,327 | 1.7 | 1.6 | 422 |
| dyspnoea | 1,208 | 1.7 | 1.6 | 366 |
| diarrhoea | 1,368 | 1.7 | 1.6 | 405 |
| fatigue | 1,283 | 1.3 | 1.3 | 103 |
| headache | 1,023 | 1.3 | 1.2 | 76 |
| off label use | 1,011 | 0.9 | 0.9 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.